Roman Drai, MD, PhD, deputy director and head of clinical operations at Geropharm, discussed Geropharm’s budding biosimilar pipeline and the company’s international pursuits during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Roman Drai, MD, PhD is the deputy director and head of clinical operations at Geropharm.
Transcript:
Can you describe Geropharm's biosimilar development and strategies for international marketing?
Geropharm is a Russian biopharmaceutical company and we produce small biosimilars and are concentrated on insulins. Now, in our pipeline, we have quite a lot of insulins [including] ultra-short-, short-, medium-, and long-acting insulins. We can cover all of the Russian market, and not only the Russian market but some other markets as well. So, we have quite a good capacity to do this. Now, in our pipeline we have not only insulins but some other peptides. I'm not sure whether I can tell you about those because they are in the early stages of development. Speaking about our global strategy, we understand that in Russia, over the last year, we got market authorizations in Russia for 3 of our insulins. And that's why we started also thinking about going abroad. We started in emerging markets from Latin America, the Far East, and we have a goal to go into the European market as well. But as for the US market, it's quite tricky for us, because we know that Europe’s journey started in 2006 and they're quite open to biosimilars. They’ve approved, by this time, already 69 biosimilars, while in the United States, [they’ve approved] just 26, and not all of them launched. We understand that the US market doesn't [embrace] biosimilars as well as the European market, because quite a lot of lobbying from big pharmaceutical companies is behind this. We see this not only in the US, but also in Russia. We are fighting with those companies. But I see that some of the US initiatives have led to an improvement for biosimilars. Still, we are not considering going to the United States at this moment, but let’s see.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
June 11th 2024Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.